554430-78-3

Upstream product

• 552-41-0 1-(2-hydroxy-4-methoxyphenyl)ethanone 
• 6496-89-5 2,4-dimethoxyphenylacetic acid 
• 108-24-7 acetic anhydride 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 829-20-9 2',4'-dimethoxyacetophenone 
• 6496-88-4 4-[(2,4-dimethoxy-phenyl)-thioacetyl]-morpholine 
• 74-88-4 methyl iodide 
• 554429-98-0 7-acetoxy-3-(2,4-dimethoxyphenyl)-4-methylcoumarin 

Downstream Products

• 909103-88-4 3-(2,4-dimethoxy-phenyl)-7-methoxy-4-(2-methoxy-ethyl)-chromen-2-one 
• 554430-80-7 3-(2,4-dimethoxy-phenyl)-7-methoxy-4-[2-(2-trimethylsilanyl-ethoxy)-ethyl]-chromen-2-one 
• 909103-94-2 4-but-3-enyl-3-(2,4-dimethoxy-phenyl)-7-methoxy-chromen-2-one 
• 909103-97-5 3-[3-(2,4-dimethoxy-phenyl)-7-methoxy-2-oxo-2H-chromen-4-yl]-propionaldehyde 
• 909103-99-7 3-(2,4-dimethoxy-phenyl)-4-(3-hydroxy-propyl)-7-methoxy-chromen-2-one 
• 909103-98-6 4-(3-bromo-propyl)-3-(2,4-dimethoxy-phenyl)-7-methoxy-chromen-2-one 
• 554430-38-5 C₁₆H₁₁BrO₅ 
• 554430-95-4 2,8-bis-(tert-butyl-dimethyl-silyloxy)-5-phenyl-5,11-dihydro-chromeno[4,3-c]-chromene 
• 554430-18-1 5-(tert-butyl-dimethyl-silyloxy)-2-[7-(tert-butyl-dimethyl-silyloxy)-4-(hydroxy-phenyl-methyl)-2H-chromen-3-yl]-phenol 
• 749901-81-3 4-bromomethyl-3-[(2,4-dimethoxy)phenyl]-7-methoxycoumarin 

Relevant academic research and scientific papers

Unexpected equivalent potency of a constrained chromene enantiomeric pair rationalized by co-crystal structures in complex with estrogen receptor alpha

Despite tremendous progress made in the understanding of the ERα signaling pathway and the approval of many therapeutic agents, ER+ breast cancer continues to be a leading cause of cancer death in women. We set out to discover compounds with a dual mechan

FUSED TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula I: (I), wherein A, A', R2A, R2B, R7, R8, R9, and R10 are defined herein. The compounds and their p

FUSED TETRACYCLIC HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Fused Tetracyclic Heterocyclic Compounds of Formula (I): wherein A, A', R2A, R2B, R7, R8, R9 and R10 are defined herein. The compounds and their pharm

Identification and structure - Activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms

As part of a program aimed at the development of selective estrogen receptor modulators (SERMs), novel chromene scaffolds, benzopyranobenzoxapanes, were discovered. Many compounds showed binding affinity as low as 1.6-200 nM, displayed antagonist behavior

Synthesis of tetracyclic heterocompounds as selective estrogen receptor modulators. Part 1. Process development for scale-up of 2,5,8-substituted 5,11 -dihydrochromeno[4,3-c]chromene derivatives

Unsymmetrical benzopyranobenzopyran compounds are novel selective estrogen receptor modulators (SERMs). A reproducible and nonchromatographic process was developed to prepare multihundred gram quantities of 5-(4-(2-(piperidin-1-yl) ethoxy)-phenyl)-5,11-di

Development of a scalable synthetic process for selective bromination of 4-methyl-3,7-substituted coumarins

The hydroxyl-protected coumarin derivatives 6a-e of 4-methyl-3-(2,4- dihydroxyphenyl)-7-hydroxycoumarin (4) are key intermediates in the synthesis of unsymmetrical benzopyranobenzopyran compounds, a novel series of selective estrogen receptor modulators (

A facile synthesis of an unsymmetric benzopyranobenzopyran ring system

A facile route to the synthesis of an unsymmetric benzopyranobenzopyran ring system is described. A key feature of this synthesis incorporates a tandem deprotection-cyclization strategy to construct the C-ring of the tetracyclic system.